Loading [MathJax]/jax/output/SVG/config.js

ZMB Member Martin Schuler

ZMB Member
Martin Schuler

Next ZMB-Member
Martin Schuler portrait
© UKE

Prof. Dr. Martin Schuler

Director of:

Department of Medical Oncology

University Hospital Essen
Hufelandstraße 55
45147 Essen

Research Overview

Clinical research

  • Biomarker-stratified early clinical drug development
  • Immuno-oncology
  • Lung cancer and thoracic oncology

Translational and clinical-related basic research

  • Mechanisms of drug resistance and immune evasion
  • Mechanisms of tumor progression and metastasis
  • Lung cancer biology

Read more

Selected Publications

    Journal articles

  • Melero, Ignacio; de Miguel Luken, Maria; de Velasco, Guillermo; Garralda, Elena; Martín-Liberal, Juan; Joerger, Markus; Alonso, Guzman; Goebeler, Maria-Elisabeth; Schuler, Martin; König, David; Dummer, Reinhard; Reig, Maria; Rodriguez Ruiz, Maria-Esperanza et al.
    Correction to: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours
    In: Nature (2025) in press
    Online Full Text: dx.doi.org/ (Open Access)
  • Schuler, Martin.
    Facts and Hopes in Neoadjuvant Immunotherapy Combinations in Resectable Non-Small Cell Lung Cancer
    In: Clinical Cancer Research Vol. 31 (2025) Nr. 5, pp. 801 - 807
    Online Full Text: dx.doi.org/
  • Felip, E.; Cho, B.C.; Gutiérrez, V.; Alip, A.; Besse, B.; Lu, S.; Spira, A.I.; Girard, N.; Califano, R.; Gadgeel, S.M.; Yang, J.C.-H.; Yamamoto, S.; Azuma, K.; Kim, Y.J.; Lee, K.-H.; Danchaivijitr, P.; Ferreira, C.G.; Cheng, Y.; Sendur, M.A.N.; Chang, G.-C et al.
    Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease : a secondary analysis from MARIPOSA
    In: Annals of Oncology Vol. 35 (2024) Nr. 9, pp. 805 - 816
    Online Full Text: dx.doi.org/ (Open Access)
  • George, Julie; Maas, Lukas; Abedpour, Nima; Cartolano, Maria; Kaiser, Laura; Fischer, Rieke N.; Scheel, Andreas H.; Weber, Jan-Philipp; Hellmich, Martin; Bosco, Graziella; Volz, Caroline; Mueller, Christian; Dahmen, Ilona; John, Felix; Alves, Cleidson Padu et al.
    Evolutionary trajectories of small cell lung cancer under therapy
    In: Nature Vol. 627 (2024) Nr. 8005, pp. 880 - 889
    Online Full Text: dx.doi.org/ (Open Access)
  • Pant, Shubham; Schuler, Martin; Iyer, Gopa; Witt, Olaf; Doi, Toshihiko; Qin, Shukui; Tabernero, Josep; Reardon, David A.; Massard, Christophe; Minchom, Anna; Lugowska, Iwona; Carranza, Omar; Arnold, Dirk; Gutierrez, Martin; Winter, Helen; Stuyckens, Kim; C et al.
    Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR) : An international, single-arm, phase 2 study
    In: The Lancet Oncology Vol. 24 (2023) Nr. 8, pp. 925 - 935
    Online Full Text: dx.doi.org/
  • Strickler, John H.; Satake, Hironaga; George, Thomas J.; Yaeger, Rona; Hollebecque, Antoine; Garrido-Laguna, Ignacio; Schuler, Martin; Burns, Timothy F.; Coveler, Andrew L.; Falchook, Gerald S.; Vincent, Mark; Sunakawa, Yu; Dahan, Laetitia; Bajor, David; R et al.
    Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer
    In: The New England Journal of Medicine Vol. 388 (2023) Nr. 1, pp. 33 - 43
    Online Full Text: dx.doi.org/ (Open Access)
  • Schuler, Martin; Zimmer, Lisa; Kim, Kevin B.; Sosman, Jeffrey A.; Ascierto, Paolo A.; Postow, Michael A.; De Vos, Filip Y.F.L.; van Herpen, Carla M.L.; Carlino, Matteo S.; Johnson, Douglas B.; Berking, Carola; Reddy, Micaela B.; Harney, Allison S.; Berlin, et al.
    Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
    In: Clinical Cancer Research Vol. 28 (2022) Nr. 14, pp. 3002 - 3010
    Online Full Text: dx.doi.org/ (Open Access)
  • Krebs, Matthew G.; Malapelle, Umberto; André, Fabrice; Paz-Ares, Luis; Schuler, Martin; Thomas, David M.; Vainer, Gilad; Yoshino, Takayuki; Rolfo, Christian.
    Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer
    In: JAMA Oncology Vol. 8 (2022) Nr. 12, pp. 1830 - 1839
    Online Full Text: dx.doi.org/
  • Fendler, Wolfgang; Pabst, Kim M.; Kessler, Lukas; Fragoso Costa, Pedro; Ferdinandus, Justin; Weber, Manuel; Lippert, Maria; Lückerath, Katharina; Umutlu, Lale; Kostbade, Karina; Mavroeidi, Ilektra A.; Schuler, Martin; Ahrens, Marit; Rischpler, Christoph; B et al.
    Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities
    In: Clinical Cancer Research Vol. 28 (2022) Nr. 19, pp. 4346 - 4353
    Online Full Text: dx.doi.org/ (Open Access)
  • Schuler, Martin.
    Corrigendum to “Inhibiting fibroblast growth factor receptors in cancer – The next generation”
    In: Annals of Oncology Vol. 32 (2021) Nr. 1, pp. 126
    Online Full Text: dx.doi.org/ (Open Access)
  • Şahin, Uǧur; Türeci, Özlem; Manikhas, Georgiy Moiseevich; Lordick, Florian; Rusyn, Andrii; Vynnychenko, Ihor A.; Dudov, Asen; Bazin, Igor S.; Bondarenko, Igor; Melichar, Bohuslav; Dhaene, Karl F.L.; Wiechen, Kai; Huber, Claudia; Maurus, Daniel; Arozullah, et al.
    FAST : a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
    In: Annals of Oncology Vol. 32 (2021) Nr. 5, pp. 609 - 619
    Online Full Text: dx.doi.org/ (Open Access)
  • Wick, Antje; Bahr, Oliver; Schuler, Martin; Rohrberg, Kristoffer; Chawla, Sant P.; Janku, Filip; Schiff, David; Heinemann, Volker; Narita, Yoshitaka; Lenz, Heinz-Josef; Ikeda, Masafumi; Ando, Yuichi; Wick, Wolfgang; Steinbach, Joachim P.; Burger, Michael C et al.
    Phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumors
    In: Clinical Cancer Research Vol. 27 (2021) Nr. 10, pp. 2723 - 2733
    Online Full Text: dx.doi.org/ (Open Access)
  • Skoulidis, Ferdinandos; Li, Bob T.; Dy, Grace K.; Price, Timothy J.; Falchook, Gerald S.; Wolf, Jürgen; Italiano, Antoine; Schuler, Martin; Borghaei, Hossein; Barlesi, Fabrice; Kato, Terufumi; Curioni-Fontecedro, Alessandra; Sacher, Adrian; Spira, Alexande et al.
    Sotorasib for Lung Cancers with KRAS p.G12C Mutation
    In: The New England Journal of Medicine Vol. 384 (2021) Nr. 25, pp. 2371 - 2381
    Online Full Text: dx.doi.org/ Online Full Text (Open Access)
  • Wiesweg, Marcel; Schuler, Martin; Schildhaus, Hans-Ulrich.
    Crizotinib in ROS1 and MET deregulated NSCLC-letter
    In: Clinical Cancer Research Vol. 26 (2020) Nr. 7, pp. 1774
    Online Full Text: dx.doi.org/ (Open Access)
  • Schuler, Martin; Berardi, Rossana; Lim, Darren Wan Teck; de Jonge, Maja J. A.; Bauer, Todd M.; Azaro, Analía; Gottfried, Maya; Han, Jiyoun; Lee, Dae-hee; Wollner, M.; Hong, David S.; Vogel, Arndt; Delmonte, Angelo; Akimov, Mikhail; Ghebremariam, Samson; Cu et al.
    Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer : Clinical and biomarker results from a phase I trial
    In: Annals of Oncology Vol. 31 (2020) Nr. 6, pp. 789 - 797
    Online Full Text: dx.doi.org/ (Open Access)
  • Schuler, Martin.
    The quest for efficient trial designs in precision oncology
    In: The Lancet Oncology Vol. 21 (2020) Nr. 12, pp. 1539 - 1541
    Online Full Text: dx.doi.org/
  • Türeci, Özlem; Sahin, Ugur; Schulze-Bergkamen, Henning; Zvirbule, Zanete; Lordick, Florian; Koeberle, Dieter; Thuss-Patience, Peter C.; Ettrich, Thomas J.; Arnold, Dirk; Bassermann, Florian; Al-Batran, Salah Eddin; Wiechen, K.; Dhaene, Karl F. L.; Maurus, et al.
    A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus : the MONO study
    In: Annals of Oncology Vol. 30 (2019) Nr. 9, pp. 1487 - 1495
    Online Full Text: dx.doi.org/ (Open Access)
  • Juric, Dejan; Janku, Filip; Rodón, Jordi; Burris, Howard A.; Mayer, Ingrid A.; Schuler, Martin; Seggewiss-Bernhardt, Ruth; Gil-Martin, Marta; Middleton, Mark R.; Baselga, José; Bootle, Douglas; Demanse, David; Blumenstein, Lars; Schumacher, Karl; Huang, Al et al.
    Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer : A Phase 1b Clinical Trial
    In: JAMA Oncology Vol. 5 (2019) Nr. 2, pp. e184475
    Online Full Text: dx.doi.org/ (Open Access)
  • Wiesweg, Marcel; Mairinger, Fabian; Reis, Henning; Goetz, Moritz; Walter, Robert; Hager, Thomas; Metzenmacher, Martin; Eberhardt, Wilfried; McCutcheon, A.; Köster, J.; Stuschke, Martin; Aigner, Clemens; Darwiche, Kaid; Schmid, Kurt Werner; Rahmann, Sven; S et al.
    Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancer
    In: Annals of Oncology Vol. 30 (2019) Nr. 4, pp. 655 - 657
    Online Full Text: dx.doi.org/ (Open Access)
  • Schuler, Martin; Cho, Byoung Chul; Sayehli, Cyrus Michael; Navarro, Alejandro; Soo, Ross A.; Richly, Heike; Cassier, Philippe Alexandre; Tai, David; Penel, Nicolas; Nogova, Lucia; Park, Se Hoon; Schostak, Martin; Gajate, Pablo; Cathomas, Richard; Rajagopal et al.
    Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression : a phase 1 dose-escalation and dose-expansion study
    In: The Lancet Oncology Vol. 20 (2019) Nr. 10, pp. 1454 - 1466
    Online Full Text: dx.doi.org/
  • Joerger, M.; Soo, R. A.; Cho, B. C.; Navarro, A.; Sayehli, C. M.; Richly, Heike; Tai, D.; Kim, D. W.; Wolf, J.; Cassier, P.; Bender, S.; Ellinghaus, P.; Ince, S.; Rajagopalan, P.; Ocker, M.; Schuler, Martin.
    A novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors : Results from rogaratinib Phase-1 study
    In: Annals of Oncology Vol. 28 (2017) Nr. Suppl. 5,
  • Al-Batran, S. E.; Pauligk, C.; Homann, N.; Schmalenberg, H.; Kopp, H. G.; Haag, G. M.; Luley, K.; Folprecht, G.; Probst, S.; Thuss-Patience, P.; Trojan, J.; Koenigsmann, M.; Lindig, U.; Pohl, M.; Kasper, Stefan; Hler, M. M.; Goetze, T.; Schuler, Martin; Ja et al.
    Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer : Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO)
    In: Annals of Oncology Vol. 28 (2017) Nr. Suppl. 5,
  • Schuler, Martin; Paz-Ares, L.; Sequist, L. V.; Wu, Y. L.; Geater, S. L.; Marten, A.; Fandrey, Joachim; Park, K.; Yang, JCH.
    First-line afatinib for advanced EGFRm1 NSCLC : Analysis of long-term responders (LTRs) in the LUX-Lung (LL) 3, 6 and 7 trials
    In: Annals of Oncology Vol. 28 (2017) Nr. Suppl. 2,
  • Guberina, M.; Eberhardt, Wilfried; Stuschke, Martin; Gauler, Thomas; Heinzelmann, F.; Cheufou, D.; Kimmich, M.; Friedel, G.; Schmidberger, H.; Darwiche, Kaid; Jendrossek, Verena; Schuler, Martin; Stamatis, Georgios; Pöttgen, Christoph.
    Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer : secondary analysis of a randomized trial
    In: Annals of Oncology Vol. 28 (2017) Nr. 5, pp. 1084 - 1089
    Online Full Text: dx.doi.org/ (Open Access)
  • Okimoto, Ross A; Breitenbücher, Frank; Olivas, Victor R; Wu, Wei; Gini, Beatrice; Hofree, Matan; Asthana, Saurabh; Hrustanovic, Gorjan; Flanagan, Jennifer; Tulpule, Asmin; Blakely, Collin M; Haringsma, Henry J; Simmons, Andrew D; Gowen, Kyle; Suh, James; M et al.
    Inactivation of Capicua drives cancer metastasis
    In: Nature Genetics Vol. 49 (2017) Nr. 1, pp. 87 - 96
    Online Full Text: dx.doi.org/ Online Full Text (Open Access)
  • Kalkavan, Halime; Sharma, Piyush; Kasper, Stefan; Helfrich, Iris; Pandyra, Aleksandra A.; Gassa, Asmae; Virchow, Isabel; Flatz, Lukas; Brandenburg, Tim; Namineni, Sukumar; Heikenwalder, Mathias; Höchst, Bastian; Knolle, Percy A.; Wollmann, Guido; Von Laer, et al.
    Spatiotemporally restricted arenavirus replication induces immune surveillance and type i interferon-dependent tumour regression
    In: Nature Communications Vol. 8 (2017) pp. 14447
    Online Full Text: dx.doi.org/ (Open Access)
  • Sequist, L.; Wu, Y. L.; Schuler, Martin; Kato, T.; Yang, JCH; Tanaka, H.; Hida, T.; Lu, S.; Park, K.; Laurie, S.; Bennouna, J.; Sibilot, D. M.; Marten, A.; Peil, B.; Ehrnrooth, E.; Yamamoto, N.; Nakagawa, K.
    Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC in LUX-Lung (LL) 3, 6 and 7
    In: Annals of Oncology Vol. 28 (2017) Nr. Suppl. 5,
    Online Full Text: dx.doi.org/
  • Cappuzzo, Federico; Soo, Ross Andrew; Hochmair, Maximilian Johannes; Schuler, Martin; Mok, Tony Shu Kam; Stehle, Gerd; Cseh, Agnieszka; Lorence, Robert M..; Linden, Stephan; Forman, Nicole D.; Tsai, Chunming.
    1236P - Global named patient use (NPU) program of afatinib, an oral ErbB family blocker, in heavily pretreated advanced non-small cell lung carcinoma (NSCLC) patients who progressed following prior therapies, including erlotinib or gefitinib (E/G)
    In: Annals of Oncology Vol. 27 (2016) Nr. Supplement 6, pp. vi427
    Online Full Text: dx.doi.org/
  • Kim, Dong-Wan; Mehra, Ranee; Tan, Daniel S W; Felip, Enriqueta; Chow, Laura Q M; Camidge, D Ross; Vansteenkiste, Johan; Sharma, Sunil; De Pas, Tommaso; Riely, Gregory J; Solomon, Benjamin J; Wolf, Jürgen; Thomas, Michael; Schuler, Martin; Liu, Geoffrey; Sa et al.
    Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1) : updated results from the multicentre, open-label, phase 1 trial
    In: The Lancet Oncology Vol. 17 (2016) Nr. 4, pp. 452 - 463
    Online Full Text: dx.doi.org/ Online Full Text (Open Access)
  • Yang, J C-H; Park, K; Kim, J-H; Bennouna, J; Chen, Y-M; Chouaid, C; De Marinis, F; Feng, J-F; Grossi, F; Kim, D-W; Liu, X; Lu, S; Strausz, J; Vinnyk, Y; Wiewrodt, R; Zhou, C; Wang, B; Chand, V K; Planchard, D; Ignatius Ou, Sai Hong; Planchard, David; Park, et al.
    Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib : phase III randomized LUX-Lung 5 trial
    In: Annals of Oncology Vol. 27 (2016) Nr. 3, pp. 417 - 423
    Online Full Text: dx.doi.org/ (Open Access)
  • Reimer, P.; Höhler, T.; Schuler, Martin; Markus, P.; Knipp, Heike; Schumacher, B.; Dechene, Alexander; Ting, Saskia; Kasper, S.; Meiler, Johannes; Kostbade, K.; Berger, W.; Herold, T.; Trarbach, Tanja; Linden, G.; Steinmetz, H.T.; Schmid, Kurt Werner; Worm et al.
    Cetuximab biweekly (q2w) plus mFOLFOX6 as 1st line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) – Primary endpoint and subgroup analysis of the CEBIFOX trial
    In: Annals of Oncology Vol. 27 (2016) Nr. Suppl.6, pp. 508P
    Online Full Text: dx.doi.org/
  • Tabernero, J.; van Geel, R.; Guren, T.; Yaeger, R.; Spreafico, A.; Faris, J.; Yoshino, T.; Yamada, Y.; Tae, W. K.; Bendell, J.; Schuler, Martin; Lenz, H. J.; Eskens, F.; Desai, J.; Hochster, H.; Avsar, E.; Demuth, T.; Sandor, V.; Elez, E.; Schellens, J.
    Combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC) : phase 2 results
    In: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 2, pp. ii127 - ii128
    Online Full Text: dx.doi.org/
  • Yang, J C-H; Sequist, L V; Zhou, C; Schuler, Martin; Geater, S L; Mok, T; Hu, C-P; Yamamoto, N; Feng, J; O'Byrne, K; Lu, S; Hirsh, V; Huang, Y; Sebastian, M; Okamoto, I; Dickgreber, N; Shah, R; Märten, A; Massey, D; Wind, S; Wu, Y-L.
    Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma : post hoc analyses of the randomized LUX-Lung 3 and 6 trials
    In: Annals of Oncology Vol. 27 (2016) Nr. 11, pp. 2103 - 2110
    Online Full Text: dx.doi.org/ (Open Access)
  • Al-Batran, Salah-Eddin; Hofheinz, Ralf D; Pauligk, Claudia; Kopp, Hans-Georg; Haag, Georg Martin; Luley, Kim Barbara; Meiler, Johannes; Homann, Nils; Lorenzen, Sylvie; Schmalenberg, Harald; Probst, Stephan; Koenigsmann, Michael; Egger, Matthias; Prasnikar, et al.
    Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO
    In: The Lancet Oncology Vol. 17 (2016) Nr. 12, pp. 1697 - 1708
    Online Full Text: dx.doi.org/
  • Al-Batran, S. E.; Schuler, Martin; Zvirbule, Z.; Manikhas, G.; Lordick, F.; Tureci, O.; Huber, C.; Sahin, U.
    IMAB362 : a novel immunotherapeutic antibody targeting the tight-junction protein component CLAUDIN18.2 in gastric cancer
    In: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 2, pp. ii141 - ii142
    Online Full Text: dx.doi.org/
  • Schuler, Martin; Yang, J. C.-H.; Planchard, D.
    Reply to the letter to the editor ‘What is the clinical impact of the LUX-Lung 5 trial?’ by Addeo
    In: Annals of Oncology Vol. 27 (2016) Nr. 6, pp. 1172 - 1173
    Online Full Text: dx.doi.org/
  • Joerger, M.; Soo, R.; Cho, B.C.; Mendivil, A. Navarro; Sayehli, C.; Richly, Heike; Tai, D.; Kim, D.-W.; Wolf, J.; Cassier, P.; Ellinghaus, P.; Hildebrandt, S.; Behre, S.; Helmbrecht, C.; Kerpen, S.; Zielinski, D.; Ince, S.; Rajagopalan, P.; Ocker, M.; Schu et al.
    developmental therapeuticsPhase I study of the pan-fibroblast growth factor receptor (FGFR) inhibitor BAY 1163877 with expansion cohorts for subjects based on tumor FGFR mRNA expression levels
    In: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, 360O_PR
    Online Full Text: dx.doi.org/
  • Wu, Y. L.; Sequist, L. V.; Geater, S. L.; Orlov, S.; Lee, K. H.; Tsai, C. M.; Kato, T.; Kiura, K.; Barrios, C. H.; Schuler, Martin; Hirsh, V.; Yamamoto, N.; OByrne, K.; Mok, T.; Massey, D.; Marten, A.; Yang, J. C. H.
    Afatinib (A) versus chemotherapy (CT) for EGFR mutation-positive NSCLC patients (pts) aged ≥65 years : Subgroup analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)
    In: Annals of Oncology Vol. 26 (2015) Nr. S 9: ESMO Asia Congress, 18-21 December 2015, Singapore : Submitted Abstracts, pp. 136 - 137
  • Schuler, Martin; Yang, J. C. H.; Park, K.; Chand, V. K.; Wang, B.; Planchard, D.
    Afatinib (a) plus paclitaxel (p) following progression on a monotherapy in patients (pts) with metastatic non-small-cell lung cancer (nsclc) who previously benefited from erlotinib (e)/gefitinib (g) : a global randomised phase iii triallux-lung 5 (ll5)
    In: Annals of Oncology Vol. 26 (2015) Nr. S 1, pp. i33 - i34
    Online Full Text: dx.doi.org/
  • Yang, James Chih-Hsin; Wu, Yi-Long; Schuler, Martin; Sebastian, Martin; Popat, Sanjay; Yamamoto, Nobuyuki; Zhou, Caicun; Hu, Cheng-Ping; O'Byrne, Kenneth; Feng, Jifeng; Lu, Shun; Huang, Yunchao; Geater, Sarayut L; Lee, Kye Young; Tsai, Chun-Ming; Gorbunova et al.
    Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6) : analysis of overall survival data from two randomised, phase 3 trials
    In: The Lancet Oncology Vol. 16 (2015) Nr. 2, pp. 141 - 151
    Online Full Text: dx.doi.org/
  • Yang, James C.-H.; Sequist, Lecia V.; Geater, Sarayut Lucien; Tsai, Chun-Ming; Mok, Tony Shu Kam; Schuler, Martin; Yamamoto, Nobuyuki; Yu, Chong-Jen; Ou, Sai-Hong I.; Zhou, Caicun; Massey, Daniel; Zazulina, Victoria; Wu, Yi-Long.
    Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations : A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
    In: The Lancet Oncology Vol. 16 (2015) Nr. 7, pp. 830 - 838
    Online Full Text: dx.doi.org/
  • George, Julie; Lim, Jing Shan; Jang, Se Jin; Cun, Yupeng; Ozretia, Luka; Kong, Gu; Leenders, Frauke; Lu, Xin; Fernández-Cuesta, Lynnette; Bosco, Graziella; Müller, Christian; Dahmen, Ilona; Jahchan, Nadine S.; Park, Kwon-Sik; Yang, Dian; Karnezis, Anthony et al.
    Comprehensive genomic profiles of small cell lung cancer
    In: Nature Vol. 524 (2015) Nr. 7563, pp. 47 - 53
    Online Full Text: dx.doi.org/ (Open Access)
  • Passaro, A.; Yang, J. C.; Ahn, M.; Dickgreber, N. J.; Halmos, B.; Hirsh, V.; Hochmair, M. J.; Levy, B. P.; de Marinis, F.; Mok, T.; OByrne, K.; Okamoto, I.; Schuler, Martin; Sebastian, M.; Shah, R.; Tan, E.; Yamamoto, N.; Marten, A.; Wind, S.; Carbone, D. et al.
    Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)
    In: Annals of Oncology Vol. 26 (2015) Nr. S 6, pp. vi73 - vi89
    Online Full Text: dx.doi.org/
  • Wu, Y. L.; Sequist, L. V.; Schuler, Martin; Yamamoto, N.; Zhou, C.; Hu, C. P.; OByrne, K.; Hirsh, V.; Mok, T.; Zazulina, V.; Yang, J. C. H.
    Overall survival (OS) with afatinib (A) vs chemotherapy (CT) in patients (pts) with NSCLC harboring EGFR mutations (mut) : Subgroup analyses by race in LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)
    In: Annals of Oncology Vol. 26 (2015) Nr. S 9: ESMO Asia Congress, 18-21 December 2015, Singapore : Submitted Abstracts, pp. 136
    Online Full Text: dx.doi.org/
  • Gautschi, Oliver; Bluthgen, Marie-Virginia; Smit, Egbert F.; Wolf, Jürgen; Früh, Martin; Petersenn, Stephan; Schuler, Martin; Zalcman, Gérard; Milia, Julie; Mazieres, Julien.
    Targeted Therapy for Patients with BRAF-Mutant Lung Cancer : Results from the European EURAF Cohort
    In: Annals of Oncology Vol. 26 (2015) Nr. S 1: European Lung Cancer Conference (ELCC), Geneva, Switzerland, 15-18 April 2015 : Abstracts, pp. i61
    Online Full Text: dx.doi.org/
  • Hyman, David M.; Puzanov, Igor; Subbiah, Vivek; Faris, Jason E.; Chau, Ian; Blay, Jean‑Yves; Wolf, Jürgen; Raje, Noopur S.; Diamond, Eli L.; Hollebecque, Antoine; Gervais, Radj; Elez‑Fernandez, Maria Elena; Italiano, Antoine; Hofheinz, Ralf‑Dieter; Hidalgo et al.
    Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations
    In: The New England Journal of Medicine Vol. 373 (2015) Nr. 8, pp. 726 - 736
    Online Full Text: dx.doi.org/ Online Full Text (Open Access)
  • Shaw, Alice T; Kim, Dong-Wan; Mehra, Ranee; Tan, Daniel S W; Felip, Enriqueta; Chow, Laura Q M; Camidge, D Ross; Vansteenkiste, Johan; Sharma, Sunil; De Pas, Tommaso; Riely, Gregory J; Solomon, Benjamin J; Wolf, Juergen; Thomas, Michael; Schuler, Martin; L et al.
    Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
    In: The New England Journal of Medicine Vol. 370 (2014) Nr. 13, pp. 1189 - 1197
    Online Full Text: dx.doi.org/ Online Full Text (Open Access)
  • Yang, J. C.; Schuler, Martin; Yamamoto, N.; OByrne, K. J.; Hirsh, V.; Mok, TSK; Massey, D.; Zazulina, V.; Shahidi, M.; Sequist, L. V.
    Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations in Lux-Lung 3, a phase III trial of afatinib or cisplatin/pemetrexed EGFR mutation-positive lung cancer
    In: Annals of Oncology Vol. 23 (2012) Nr. Suppl. 9, pp. 410 - 411
  • Sequist, L. V.; Schuler, Martin; Yamamoto, N.; OByrne, K. J.; Hirsh, V.; Mok, TSK; Lungershausen, J.; Shahidi, M.; Palmer, M.; Yang, J. C.
    LUX-Lung 3 : Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutations
    In: Annals of Oncology Vol. 23 (2012) Nr. Suppl. 9, pp. 402
  • Yamamoto, N.; Schuler, Martin; OByrne, K.; Hirsh, V.; Mok, T.; Kato, T.; Yoshioka, H.; Okamoto, I.; Yokoyama, A.; Massey, D.; Jones, H.; Zazulina, V.; Shahidi, M.; Sequist, L.; Yang, JCH.
    Lux-LungG 3 : Afatinib versus cisplatin and pemetrexed in Japanese patients with adenocarcinoma of the lung harboring an EGFR mutation
    In: Annals of Oncology Vol. 23 (2012) Nr. Suppl. 11, pp. 8
  • Dirix, L.; Schuler, Martin; Machiels, J.; Hess, D.; Awada, A.; Steeghs, N.; Paz-Ares, L.; von Moos, R.; Rabault, B.; Rodon, J.
    Phase IB dose-escalation study of BEZ235 or BKM 120 in combination with paclitaxel (PTX) in patients with advanced solid tumors
    In: Annals of Oncology Vol. 23 (2012) Nr. Suppl. 9, pp. 157 - 158
  • Schmidt, Markus; Rüttinger, Dominik; Sebastian, M.; Hanusch, Claus A.; Marschner, Norbert; Bäuerle, Patrick A.; Wolf, Andreas; Göppel, Gertrud; Oruzio, Daniel; Schlimok, Günter; Steger, Günther G.; Wolf, Christopher; Eiermann, Wolfgang; Lang, Alois; Schule et al.
    Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with epcampositive relapsed or refractory advanced-stage breast cancer
    In: Annals of Oncology Vol. 23 (2012) Nr. 9, pp. 2306 - 2313
    Online Full Text: dx.doi.org/ (Open Access)
  • Schmidt, Martina; Scheulen, Max Ernst; Dittrich, C.; Obrist, P.; Marschner, N.; Dirix, L.; Schmidt, M.; Rüttinger, D.; Schuler, Martin; Reinhardt, C.; Awada, A.
    An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer
    In: Annals of Oncology Vol. 21 (2010) Nr. 2, pp. 275 - 282
    Online Full Text: dx.doi.org/
  • Petry, I. B.; Fieber, E.; Schmidt, Marcus; Gehrmann, M.; Gebhard, S.; Hermes, M.; Schormann, W.; Selinski, S.; Freis, E.; Schwender, H.; Brulport, M.; Ickstadt, K.; Rahnenführer, J.; Maccoux, L.; West, J.; Kölbl, H.; Schuler, Martin; Hengstler, J. G.
    ERBB2 Induces an Antiapoptotic Expression Pattern of Bcl-2 Family Members in Node-Negative Breast Cancer
    In: Clinical Cancer Research Vol. 16 (2010) Nr. 2, pp. 451 - 460
    Online Full Text: dx.doi.org/
Read more